One of the factors that is augmenting the growth of the market is the increasing demand for PET analysis in radiopharmaceuticals. According to the World Nuclear Organization, there are over 20 million nuclear medicine procedures per year among 311 million people in the United States, about 10 million among 500 million people in Europe, and about 560,000 per year among 21 million people in Australia. SPECT and PET systems dominate the field of nuclear medicine market. Technological advancements, like the introduction of Time of Flight (TOF), as well as the rise in increasing popularity of the hybrid imaging systems, play an important role in the growth of the nuclear imaging market. The hybrid imaging using combined scanners, like SPECT/CT, PET/CT, and PET/MRI, is likely to propel the growth of the industry in the future. A study reveals that, in 2014, an estimated 11.7 million patients received nuclear medicine scans, on over 14,000 SPECT or SPECT/CT scanners, in the United States. In 2015, an estimated 220,800 new cases of prostate cancer were diagnosed in North America, and 27,540 men died of the disease. Supported by a USD 2.6 million grant from the National Institutes of Health, a novel PET imaging agent, 64Cu-TP3805, was developed to diagnose prostate cancer. Using this procedure, more than 80% of cancers were detected. Arsenic 72 and (18F)-3’-fluoro-3’-deoxythymidine (18F-FLT) are newer biomarkers in the PET oncological practice. Thus, these advances in approaches are expected to strengthen personalized medicine. Based on all the aforementioned key contributing factors, continued growth can be expected during the forecast period
Key Market Trends
Oncology is Expected to Hold the Largest Share of the Positron Emission Tomography Market, over the Forecast Period
The 18Fluorine-2-fluoro-2-Deoxy-d-glucose (18F-FDG) PET scanners are the most widely used imaging technique in oncology. Apart from imaging, PET scanners are commonly used into clinical trials, as an imaging biomarker, to determine the therapeutic response to novel cancer therapeutics. According to an article by Andrea Gallamini et. al, the most apparent advantages associated with PET is its ability to detect the substantial changes in glucose metabolism, or even complete shutoff of the neoplastic cell metabolism in the early stages, during the treatment process. This helps the clinicians to detect the effectiveness of a given antineoplastic treatment much earlier, compared to the traditional radiological detection. Furthermore, FDG-PET/CT has become a cornerstone in several oncologic procedures, such as tumour staging and restaging, treatment efficacy assessment during or after treatment ends, and radiotherapy planning.
The number of cancer cases is increasing yearly. According to WHO, Cancer is the second-leading cause of death globally, and was responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is caused due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries. Thus, the need for early diagnosis and treatment of cancer cases has enhanced the usage of PET scanners, and has led to the growth of the market.
North American Region Holds the Largest Market Share of the Positron Emission Tomography Market
North America dominates the positron emission tomography market, owing to the high demand for precision diagnostics and technological advancement in PET technology in the region. Other factors that contribute to the growth of the PET market in the United States include government initiatives, such as Medicare and Obama Care, which provide healthcare to patients through democratic supervision.
The market consists of several major players. The comapanies are implementing certain strategic initiatives, such as a mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. For instance, in December 2017, Conemaugh Memorial Medical Center had invested in new PET/CT technology that benefits patients, by providing a high-quality image in half the time with half the radiation.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support